245 related articles for article (PubMed ID: 28166827)
1. The polypill approach - An innovative strategy to improve cardiovascular health in Europe.
Fuster V; Gambús F; Patriciello A; Hamrin M; Grobbee DE
BMC Pharmacol Toxicol; 2017 Feb; 18(1):10. PubMed ID: 28166827
[TBL] [Abstract][Full Text] [Related]
2. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
3. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular polypill: clinical data and ongoing studies.
Castellano JM; Bueno H; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
[TBL] [Abstract][Full Text] [Related]
5. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
6. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Tamargo J; Castellano JM; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
[TBL] [Abstract][Full Text] [Related]
7. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
8. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.
Selak V; Elley CR; Crengle S; Harwood M; Doughty R; Arroll B; Bryant L; Rafter N; Hoorn SV; Wadham A; Wells S; Milne R; Jackson R; Bramley D; Rodgers A
Contemp Clin Trials; 2011 Nov; 32(6):909-15. PubMed ID: 21777702
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.
Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z
Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377
[TBL] [Abstract][Full Text] [Related]
10. Polypill treatments for cardiovascular diseases.
Webster R; Rodgers A
Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
[TBL] [Abstract][Full Text] [Related]
12. Patient preferences for a polypill for the prevention of cardiovascular diseases.
Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
[TBL] [Abstract][Full Text] [Related]
13. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
14. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
15. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
Grigorian-Shamagian L; Coca A; Morais J; Perez-Martinez P;
BMC Proc; 2023 Aug; 17(Suppl 8):20. PubMed ID: 37587509
[TBL] [Abstract][Full Text] [Related]
16. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
[TBL] [Abstract][Full Text] [Related]
18. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
Sanz G; Fuster V
Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
[TBL] [Abstract][Full Text] [Related]
19. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
20. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A
Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
